Navigation Links
Alimera Sciences Reports Third Quarter 2013 Financial Results
Date:11/11/2013

e to common shareholders and net loss per common share to adjusted net loss per common share, see the table below.

Forward Looking StatementsThis press release contains "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, Alimera's commercial plans for ILUVIEN in Germany, the United Kingdom and France and the regulatory status of ILUVIEN in the United States and the 10 additional EU countries for which Alimera is seeking approvals through the Mutual Recognition Procedure. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in its forward-looking statements. Meaningful factors which could cause actual results to differ include, but are not limited to, uncertainty as to Alimera's ability to commercialize, and market acceptance of, ILUVIEN in the EU, as well as other factors discussed in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Alimera's Annual Report on Form 10-K for the year ended December 31, 2012 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2013, which are on file with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov. Additional factors may also be set forth in those sections of Alimera's Quarterly Report on Form 10-Q for the quarter ended September 30, 2013 to be filed with the SEC in the fourth quarter of 2013. In addition to the risks described above and in Alimera's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, other unknown or unpredictable factors also could affect Alimera's results. There can be no assurance that the actua
'/>"/>

SOURCE Alimera Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Alimera Sciences to Release Third Quarter 2013 Results and Provide Update on Upcoming FDA Advisory Committee Meeting
2. Alimera Sciences Reports Second Quarter 2013 Financial Results
3. Alimera Sciences to Release Second Quarter Fiscal Year 2013 Financial Results
4. Alimera Sciences Reports First Quarter 2013 Financial Results
5. Alimera Sciences Secures $20 Million Debt Facility
6. Alimera Sciences To Release First Quarter Fiscal Year 2013 Financial Results
7. Alimera Sciences Reports Fourth Quarter 2012 Financial Results
8. Alimera Sciences To Release Fourth Quarter And Fiscal Year 2012 Financial Results
9. Alimera Sciences Participating in Credit Suisse London One-on-One Healthcare Conference
10. Alimera Sciences Names European Management Team
11. Alimera Sciences To Present At Credit Suisse 2012 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)...  InnoPharma, Inc. today announced the first generic launch ... Zyprexa® injection), in Canada.  Olanzapine is indicated for the ... with schizophrenia or bipolar I mania. As ... entered into an agreement with Sandoz Canada Inc., pursuant ... sell, market and distribute Olanzapine Injection in ...
(Date:7/30/2014)... KISSING, Germany , July 30, 2014 ... single use and computer-assisted ("robotic") colonoscopy system, today announced ... worldwide recognized medical device executive, as a new member ... is a highly respected global visionary in the medical ... as President and Chief Executive Officer at Given Imaging ...
(Date:7/30/2014)... CLARA, Calif. , July 30, 2014 ... economy, released a study today that examines ... biopharma and medical device companies.  According to the annual ... saw the biggest potential returns since SVB started tracking ... year of the IPO.  Built on solid healthcare M&A ...
Breaking Medicine Technology:InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3
... media worldwide report almost on a weekly basis about ... study finds that olive polyphenols can inactivate one of ... today,s most deadly food poisoning occurrences. ... Western Regional Center, a group of USDA researchers led ...
... Aug. 11, 2011 Unilife Corporation ("Unilife" ... UNS) today announced strategic additions to its management team. ... launch of the Unifill ® ready-to-fill (prefilled) syringe ... well as accelerate the commercialization of other pipeline devices ...
Cached Medicine Technology:Scientists at USDA Says CREAGRI HIDROX® Effective Against Staphylococcus aureus Bacteria and Staphylococcus Enterotoxin A 2Unilife Expands Management Team to Support Business Growth 2Unilife Expands Management Team to Support Business Growth 3Unilife Expands Management Team to Support Business Growth 4Unilife Expands Management Team to Support Business Growth 5Unilife Expands Management Team to Support Business Growth 6
(Date:7/30/2014)... 2014 Good Neighbor Community Services ... upcoming episode of Innovations with Ed Begley Jr, ... and show times TBA. , In this segment, ... Services’ vision to redefine the traditional approach to ... services. Through passion, innovation, determination, excellence, and collaboration, ...
(Date:7/30/2014)... SF Cable, distributor of the highest ... on the internet with guaranteed customer satisfaction announces the ... two colors. These lightning cords are MFI certified to ... quality SF Cable Lightning to USB Cables ... faster charging and syncing. Compatible with the iPhone 5S/5C/5 ...
(Date:7/30/2014)... Hamilton Facial Plastic Surgery ... Carmel office on July 30th. After months of planning, ... to the state-of-the-art suite, located only steps away from ... allow for one-on-one patient comfort, shorter wait times, and ... Dr. Hamilton’s new office-suite will continue to provide the ...
(Date:7/30/2014)... ... ... ... , UCLA researchers interviewed people with diverticulitis and confirmed that many suffer psychological and physical symptoms long ... , a UCLA team led by Dr. Brennan Spiegel interviewed patients in great detail about the symptoms they experience weeks, months or ...
(Date:7/30/2014)... York (PRWEB) July 30, 2014 As ... http://www.injurybeacon.com/power-morcellator/ ) in gynecological surgeries continues to grow, Bernstein ... voice to those calling for a ban on uterine ... Debra Valverde was diagnosed with leiomyosarcoma following a hysterectomy ... a year of her diagnosis, the aggressive cancer had ...
Breaking Medicine News(10 mins):Health News:Good Neighbor Community Services to be Featured in an Upcoming Episode of Innovations With Ed Begley, Jr. 2Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 3Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 3Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 4
... to Better ... of Treatment Options, WASHINGTON, Nov. 2 Today, ... organization for interventional cardiology, announced the,launch of Seconds Count, ... for an authoritative resource about cardiovascular disease and,treatment. The ...
... Kensey Nash Corporation,(Nasdaq: KNSY ) today announced ... Coherence Domain Reflectometry Guidewire, from Lawrence,Livermore National Security, ... to its chronic total occlusion (CTO) platform.,The patent ... it to sense locations, thickness, and structure of ...
... CPR, assistance, measuring pain medication effectiveness, improving cancer ... ... A novel way to treat cancer,has won the top honor at the ... Fame Foundation. Ian,Cheong of Johns Hopkins University was announced as the grand ...
... of the time,that sales people should be spending with the ... Pharmaceutical sales directors agree the answer is ,too much time, ... - or 6 weeks per rep,per year - is unnecessary ... recent research study by Best Practices, LLC. But yet,understanding and ...
... LAWRENCE, Mass., Nov. 2 NxStage Medical, Inc.,(Nasdaq: ... portable,kidney dialysis machine, today announced its financial results for ... the third quarter of 2007 were $11.6 million, compared ... increase of 111%. Revenues in,the chronic home dialysis market ...
... demonstrates >99% mean decrease in HCV RNA ... with no serious adverse events-, PRINCETON, ... results of a 14-day Phase 1 multiple ascending,dose monotherapy study of ... being presented as a "late-breaker" abstract at,the 58th Annual Meeting of ...
Cached Medicine News:Health News:New Web Site Helps Patients Navigate Heart Disease Treatment Options 2Health News:New Web Site Helps Patients Navigate Heart Disease Treatment Options 3Health News:Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform 2Health News:Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform 3Health News:Collegiate Inventors Competition(R) Announces Winners for 2007 2Health News:Collegiate Inventors Competition(R) Announces Winners for 2007 3Health News:Collegiate Inventors Competition(R) Announces Winners for 2007 4Health News:Collegiate Inventors Competition(R) Announces Winners for 2007 5Health News:New Pharmaceutical Sales Force Communication Metrics: Nearly 6 Weeks of Sales Time per Rep Wasted Each Year 2Health News:NxStage Medical Reports Third Quarter 2007 Results 2Health News:NxStage Medical Reports Third Quarter 2007 Results 3Health News:NxStage Medical Reports Third Quarter 2007 Results 4Health News:NxStage Medical Reports Third Quarter 2007 Results 5Health News:NxStage Medical Reports Third Quarter 2007 Results 6Health News:NxStage Medical Reports Third Quarter 2007 Results 7Health News:NxStage Medical Reports Third Quarter 2007 Results 8Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 2Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 3Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 4Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 5
... Plus Instrument for applications ... ,The VERSASTEP™ Plus ... working length is a ... utilizing radial dilation. It ...
... system device is comprised of the following ... access port are also packaged in the ... cone with 12 mm Step™ cannula assembly ... 12 mm locking cone with 10/12 mm ...
... The Step™ and Mini Step™ device components are ... Step™ Single Use System is supplied sterile in ... packaged in various configurations and combinations. They are ... Access needle and the Step™ radially Expandable Sleeve. ...
... The Premium One-Step™ single-use system device is ... ,The device components for creating each access ... configurations: , Step™ insufflation and access ... packaged separately. , Step™ radially expandable sleeve, ...
Medicine Products: